At Cureport we seek to deliver innovative nanomedicines to ultimately benefit patients. We aspire to be a global leader in nanomedicine innovation and development. We strive to build up values to people, our employees and shareholders.
Cureport, Inc. is a growing U.S. pharmaceutical company committed to the development of nanomedicines. With a strong VC investment, Cureport has established its nPort™ nanotechnology for drug delivery of both small molecules and biological molecules for the treatment of cancer, infectious and other diseases. It brought a revolutionary breakthrough to the manufacture of liposomal products through an innovative controlled self-assembly process. Cureport develops its core technologies in-house and contracts with CRO/CMO for regular research and GMP productions. Cureport is working with its affiliated company Curecon to build its pilot manufacture base and R&D center in Beijing, China.
In order to ultimately exert the advantage of nPort™ technology, Cureport directs its business mainly in 3 directions: